QT interval prolongation related to afatinib treatment in a patient with metastatic non–small-cell lung cancer

Demircan, Nazım Can; Telli, Tuğba Akın; Tüylü, Tuğba Başoğlu; Arıkan, Rukiye; Kocakaya, Derya; Şahin, Ahmet Anıl; Ercelep, Özlem; Dane, Faysal; Yumuk, Perran Fulden

doi:10.1016/j.currproblcancer.2020.100594

Cited by 6 publications

(4 citation statements)

References 11 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…In addition, through the different effects of the three drugs on cardiomyocytes, osimertinib has the most obvious effect on cardiomyocytes at a low concentration, and getinib has the greatest damage to cells with the increase of concentration, while afatinib has the least effect on cardiomyocytes, which is similar to the conclusion of relevant literature. 14,17,41 The study of the mechanical properties of cardiomyocytes can help to understand the principle of the damage caused by drugs to the heart, thus helping to screen and develop drugs for treating cancer.…”

Section: Discussionmentioning

confidence: 99%

“…Recently, a number of adverse events (AEs) related to the cardiotoxicity of EGFR-TKIs have been reported, which is a major concern during the therapy. [9][10][11][12][13][14][15][16][17][18][19][20] The most common symptoms are QT prolongation, atrial brillation (AF), cardiomyocyte hypertrophy, ejection fraction reductions, and cardiac failure. It has been suggested that EGFR-TKIs have a similar effect to trastuzumab, a monoclonal antibody against human EGFR2 (HER2).…”

Section: Introductionmentioning

confidence: 99%

See 1 more Smart Citation

Effects of targeted lung cancer drugs on cardiomyocytes studied by atomic force microscopy

et al. 2023

View full text Add to dashboard Cite

show abstract

Section: Discussionmentioning

confidence: 99%

Section: Introductionmentioning

confidence: 99%

Effects of targeted lung cancer drugs on cardiomyocytes studied by atomic force microscopy

et al. 2023

View full text Add to dashboard Cite

show abstract

“…Elucidating the molecular mechanisms of the initiation and development of NSCLC would benefit the early diagnosis and targeted therapy efforts [ 60 – 63 ]. In this study, we identified 1,362 upregulated genes and 49 downregulated genes and selected GNGT1, GNG4, NMU, GCG, TAC1, GAST NPSR1, and GCGR as hub genes using Molecular Complex Detection (MCODE) and cytoHubba.…”

Section: Discussionmentioning

confidence: 99%

Identified GNGT1 and NMU as Combined Diagnosis Biomarker of Non-Small-Cell Lung Cancer Utilizing Bioinformatics and Logistic Regression

Zhang

Jiang

et al. 2021

Disease Markers

View full text Add to dashboard Cite

Non-small-cell lung cancer (NSCLC) is one of the most devastating diseases worldwide. The study is aimed at identifying reliable prognostic biomarkers and to improve understanding of cancer initiation and progression mechanisms. RNA-Seq data were downloaded from The Cancer Genome Atlas (TCGA) database. Subsequently, comprehensive bioinformatics analysis incorporating gene ontology (GO), Kyoto Encyclopedia of Genes and Genomes (KEGG), and the protein-protein interaction (PPI) network was conducted to identify differentially expressed genes (DEGs) closely associated with NSCLC. Eight hub genes were screened out using Molecular Complex Detection (MCODE) and cytoHubba. The prognostic and diagnostic values of the hub genes were further confirmed by survival analysis and receiver operating characteristic (ROC) curve analysis. Hub genes were validated by other datasets, such as the Oncomine, Human Protein Atlas, and cBioPortal databases. Ultimately, logistic regression analysis was conducted to evaluate the diagnostic potential of the two identified biomarkers. Screening removed 1,411 DEGs, including 1,362 upregulated and 49 downregulated genes. Pathway enrichment analysis of the DEGs examined the Ras signaling pathway, alcoholism, and other factors. Ultimately, eight prioritized genes (GNGT1, GNG4, NMU, GCG, TAC1, GAST, GCGR1, and NPSR1) were identified as hub genes. High hub gene expression was significantly associated with worse overall survival in patients with NSCLC. The ROC curves showed that these hub genes had diagnostic value. The mRNA expressions of GNGT1 and NMU were low in the Oncomine database. Their protein expressions and genetic alterations were also revealed. Finally, logistic regression analysis indicated that combining the two biomarkers substantially improved the ability to discriminate NSCLC. GNGT1 and NMU identified in the current study may empower further discovery of the molecular mechanisms underlying NSCLC’s initiation and progression.

show abstract

“…13) Demircan, et al reported a 42year-old female patient with pulmonary adenocarcinoma showed QT prolongation after 7-week treatment of 40 mg/ day afatinib, requiring a dose reduction to 30 mg/day for the avoidance of the recurrence of QT prolongation. 14) Osimertinib (Tagrisso): The Japanese interview-form of osimertinib reports 21 (3.8%) cardiovascular events from 558 cases, which include 3 heart failure (0.5%), 1 myocardial infarction (0.2%), 2 arrhythmia (0.4%), 3 deep vein thrombosis (0.5%), 3 hypertension (0.5%), and 9 others (1.6%).…”

Section: Afatinib (Giotrif)mentioning

confidence: 99%

Cardiovascular Complications by EGFR Tyrosine Kinase Inhibitors in Patients with Lung Cancer

Kimura

Morita

2021

Int. Heart J.

View full text Add to dashboard Cite

QT interval prolongation related to afatinib treatment in a patient with metastatic non–small-cell lung cancer

Cited by 6 publications

References 11 publications

Effects of targeted lung cancer drugs on cardiomyocytes studied by atomic force microscopy

Effects of targeted lung cancer drugs on cardiomyocytes studied by atomic force microscopy

Identified GNGT1 and NMU as Combined Diagnosis Biomarker of Non-Small-Cell Lung Cancer Utilizing Bioinformatics and Logistic Regression

Cardiovascular Complications by EGFR Tyrosine Kinase Inhibitors in Patients with Lung Cancer

Contact Info

Product

Resources

About